乙硫异烟胺药效学指导剂量、MIC对临床结局的作用及耐药时间箭头
该研究通过结核中空纤维系统模型确定乙硫异烟胺AUC0-24/MIC>56.2为目标暴露,蒙特卡洛模拟显示20 mg/kg/天可使>95%患者达标(Sensititre MIC<2.5 mg/L)。坦桑尼亚患者分析表明乙硫异烟胺MIC与痰培养转阴时间呈线性负相关,MIC>2.5 mg/L时联合治疗失败。
要点
- 乙硫异烟胺目标暴露为AUC0-24/MIC>56.2。
- 20 mg/kg/天可使>95%患者达标,需Sensititre MIC<2.5 mg/L。
- MIC>2.5 mg/L时MDR-TB联合治疗失败。
核心结论
- 乙硫异烟胺是MDR-TB治疗方案的重要组成,在Sensititre MIC<2.5 mg/L时有效。
- 亚optimal乙硫异烟胺暴露导致外排泵介导的获得性耐药。
研究设计与样本
- 多剂量结核中空纤维系统模型研究,结合全基因组和Sanger测序。
- 蒙特卡洛实验模拟10000例肺结核患者。
- 坦桑尼亚患者队列使用多变量自适应回归样条分析。
主要发现
- HFS-TB中AUC0-24/MIC>56.2为目标暴露。
- 乙硫异烟胺单药早期诱导外排泵导致乙胺丁醇和异烟肼同时耐药,削弱微生物杀灭。
- 单药期间分离株测序显示ethA和embA突变。
- MCEs中20 mg/kg/天在>95%患者达到AUC0-24/MIC>56.2(Sensititre MIC<2.5 mg/L)。
- 临床中乙硫异烟胺Sensititre MIC与痰转阴时间线性负相关至MIC 2.5 mg/L,以上则联合治疗失败。
关键数值与推荐
- 目标暴露:AUC0-24/MIC>56.2。
- 剂量:20 mg/kg/天,条件Sensititre MIC<2.5 mg/L。
- MIC阈值:2.5 mg/L,以上联合治疗失败。
临床怎么用
- 使用乙硫异烟胺治疗MDR-TB时,应确保Sensititre MIC<2.5 mg/L。
- 推荐剂量20 mg/kg/天以达到目标暴露。
- 监测MIC以避免亚optimal暴露导致的获得性耐药。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Ethionamide is used to treat multidrug-resistant tuberculosis (MDR-TB). The antimicrobial pharmacokinetics/pharmacodynamics, the contribution of ethionamide to the multidrug regimen, and events that lead to acquired drug resistance (ADR) are unclear. METHODS: We performed a multidose hollow fiber system model of tuberculosis (HFS-TB) study to identify the 0-24 hour area under the concentration-time curve (AUC0-24) to minimum inhibitory concentration (MIC) ratios that achieved maximal kill and ADR suppression, defined as target exposures. Ethionamide-resistant isolates underwent whole-genome and targeted Sanger sequencing. We utilized Monte Carlo experiments (MCEs) to identify ethionamide doses that would achieve the target exposures in 10000 patients with pulmonary tuberculosis. We also identified predictors of time-to-sputum conversion in Tanzanian patients on ethionamide- and levofloxacin-based regimens using multivariate adaptive regression splines (MARS). RESULTS: An AUC0-24/MIC >56.2 was identified as the target exposure in the HFS-TB. Early efflux pump induction to ethionamide monotherapy led to simultaneous ethambutol and isoniazid ADR, which abrogated microbial kill of an isoniazid-ethambutol-ethionamide regimen. Genome sequencing of isolates that arose during ethionamide monotherapy revealed mutations in both ethA and embA. In MCEs, 20 mg/kg/day achieved the AUC0-24/MIC >56.2 in >95% of patients, provided the Sensititre assay MIC was <2.5 mg/L. In the clinic, MARS revealed that ethionamide Sensititre MIC had linear negative relationships with time-to-sputum conversion until an MIC of 2.5 mg/L, above which patients with MDR-TB failed combination therapy. CONCLUSIONS: Ethionamide is an important contributor to MDR-TB treatment regimens, at Sensititre MIC <2.5 mg/L. Suboptimal ethionamide exposures led to efflux pump-mediated ADR.
引用
- Deshpande D, Pasipanodya JG, Mpagama SG, et al. Ethionamide Pharmacokinetics/Pharmacodynamics-derived Dose, the Role of MICs in Clinical Outcome, and the Resistance Arrow of Time in Multidrug-resistant Tuberculosis. Clin Infect Dis. 2018. PMID: 30496457. doi:10.1093/cid/ciy609
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。